Intuitive Surgical's Guthart: "The first rule of being disruptive is having people who believe they can change the world"

March 28, 2012 by Brian Johnson

MassDevice discusses innovation, robotic surgery and Silicon Valley culture with Intuitive Surgical CEO Gary Guthart.

Gary Guthart knows a little something about disruptive innovation.

The 45-year-old CEO of Intuitive Surgical (NSDQ:ISRG) has been working to change the way minimally invasive surgery is performed since his days on the research team at SRI (formerly Stanford Research Institute). That group of Silicon Valley pioneers helped lay the foundation for the computer-enhanced surgery technology that helped launch the Sunnyvale, Calif.-based Intuitive. Named head of engineering in his early 30s, Guthart worked his way up the ranks at ISRG under predecessor Lonnie Smith, who took a seat on the board in early 2010 when Guthart took over the corner office.

Sign up to get our free newsletters delivered straight to your inbox

So far Guthart has delivered, increasing top-line performance 34% in his 1st year and opening up the da Vinci robot for several additional procedures. If the da Vinci truly changes the face of surgery, as the company claims it can, it will likely be under Guthart's watch.

Last year MassDevice named him one of the 5 most innovative CEOs in the industry. We caught up with him recently for a wide-ranging discussion on what makes him tick and what keeps Intuitive humming. We also discussed a recent study that questioned whether the cost of robotic surgery was worth price and what the future for computer-aided surgery looks like.

MassDevice: You started this journey as part of the core team at SRI. What was the central problem you addressed and did you solve it?

Comments

Features

ResMed CEO Mick Farrell tells MassDevice.com about the history of ResMed, its sleep apnea devices and the future of treating chronic disease.

Dr. Robert Greenberg, founder & CEO of Second Sight Medical, chats with MassDevice.com in advance of his appearance at the Big 100 West to discuss the Argus II 'bionic eye.'

CEO Josh Kornberg tells MassDevice.com about cleaning house and how bad news for rival Stryker Corp. is helping to reinvigorate Skyline Medical.

In this MassDevice.com podcast, we speak with Glooko CEO Rick Altinger about the company's mobile diabetes management application for smartphones and how it has the potential to change the spectrum of care for one of the world's most common chronic diseases.

Renal denervation has won a lot of praise as a potential solution for patients with resistant hypertension, but the excessive celebration of early clinical trial results may be setting everyone up for a major letdown and a harsh backlash. This week cardiologists at the Transcatheter Cardiovascular Therapeutics conference, including those involved with Medtronic's and Boston Scientific's clinical trials, warned of the dangers of exaggeration.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp